There are three generally recognized classes which include cancer vaccines (e.g. bacille Calmette-Guérin), tumor-targeting antibodies (e.g. enfortumab and sacituzumab) and immunomodulators (e.g. PD1/PDL1 inhibitor) [6]. Here, CD274 is linked to cancer.